Literature DB >> 33762397

JAK-inhibition as a therapeutic strategy for refractory primary systemic vasculitides.

Sujoy Khan1.   

Abstract

Mesh:

Year:  2021        PMID: 33762397      PMCID: PMC8002766          DOI: 10.7861/clinmed.Let.21.2.2

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  9 in total

1.  Intestinal Behçet's Disease with Primary Myelofibrosis Involving Trisomy 8.

Authors:  Taisuke Narazaki; Motoaki Shiratsuchi; Mariko Tsuda; Yasuhiro Tsukamoto; Hiroki Muta; Toru Masuda; Daisaku Kimura; Akiko Takamatsu; Ryota Nakanishi; Eiji Oki; Minako Fujiwara; Yoshinao Oda; Yasuhiro Nakashima; Yoshihiro Ogawa
Journal:  Acta Haematol       Date:  2019-07-10       Impact factor: 2.195

2.  Tofacitinib for polyarteritis nodosa: a tailored therapy.

Authors:  Doron Rimar; Ayelet Alpert; Elina Starosvetsky; Itzhak Rosner; Gleb Slobodin; Michael Rozenbaum; Lisa Kaly; Nina Boulman; Abid Awisat; Shira Ginsberg; Karina Zilber; Shai S Shen-Orr
Journal:  Ann Rheum Dis       Date:  2016-08-24       Impact factor: 19.103

3.  A pilot study of tofacitinib for refractory Behçet's syndrome.

Authors:  Jinjing Liu; Yunxia Hou; Luxi Sun; Chaoran Li; Lu Li; Yan Zhao; Xiaofeng Zeng; Fengchun Zhang; Wenjie Zheng
Journal:  Ann Rheum Dis       Date:  2020-05-27       Impact factor: 19.103

4.  Th1 and Th17 cytokines drive inflammation in Takayasu arteritis.

Authors:  D Saadoun; M Garrido; C Comarmond; A C Desbois; F Domont; L Savey; B Terrier; G Geri; M Rosenzwajg; D Klatzmann; P Fourret; P Cluzel; L Chiche; J Gaudric; F Koskas; P Cacoub
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

5.  Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Correspondence on 'Tofacitinib for polyarteritis nodosa: a tailored therapy' by Rimar et al.

Authors:  Mitsuhiro Akiyama; Yuko Kaneko; Tsutomu Takeuchi
Journal:  Ann Rheum Dis       Date:  2020-09-09       Impact factor: 27.973

6.  An update on the general management approach to common vasculitides.

Authors:  Mooikhin Hng; Sizheng S Zhao; Robert J Moots
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

7.  Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis.

Authors:  Saki Kuwabara; Shun Tanimura; Shogo Matsumoto; Hiroyuki Nakamura; Tetsuya Horita
Journal:  Ann Rheum Dis       Date:  2020-03-25       Impact factor: 27.973

8.  JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.

Authors:  Gina A Montealegre Sanchez; Adam Reinhardt; Suzanne Ramsey; Helmut Wittkowski; Philip J Hashkes; Yackov Berkun; Susanne Schalm; Sara Murias; Jason A Dare; Diane Brown; Deborah L Stone; Ling Gao; Thomas Klausmeier; Dirk Foell; Adriana A de Jesus; Dawn C Chapelle; Hanna Kim; Samantha Dill; Robert A Colbert; Laura Failla; Bahar Kost; Michelle O'Brien; James C Reynolds; Les R Folio; Katherine R Calvo; Scott M Paul; Nargues Weir; Alessandra Brofferio; Ariane Soldatos; Angelique Biancotto; Edward W Cowen; John J Digiovanna; Massimo Gadina; Andrew J Lipton; Colleen Hadigan; Steven M Holland; Joseph Fontana; Ahmad S Alawad; Rebecca J Brown; Kristina I Rother; Theo Heller; Kristina M Brooks; Parag Kumar; Stephen R Brooks; Meryl Waldman; Harsharan K Singh; Volker Nickeleit; Maria Silk; Apurva Prakash; Jonathan M Janes; Seza Ozen; Paul G Wakim; Paul A Brogan; William L Macias; Raphaela Goldbach-Mansky
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

9.  Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis.

Authors:  Kotaro Matsumoto; Katsuya Suzuki; Keiko Yoshimoto; Noriyasu Seki; Hideto Tsujimoto; Kenji Chiba; Tsutomu Takeuchi
Journal:  Arthritis Res Ther       Date:  2019-12-30       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.